Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacob George

Showing results (721-730 of 849) with videos related to

Pageof 85
Sort By:
Metabolism: Clinical and Experimental|April 18, 2016
Opposite associations between alanine aminotransferase and γ-glutamyl transferase levels and all-cause mortality in type 2 diabetes: Analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) studyKathryn H Williams, David R Sullivan, Geoffrey C Nicholson, et al.
Hepatology (Baltimore, Md.)|January 18, 2013
Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infectionJason Grebely, Jordan J Feld, Tanya Applegate, et al.
Diabetes, Obesity & Metabolism|September 17, 2024
Associations between cuprotosis-related genes and the spectrum of metabolic dysfunction-associated fatty liver disease: An exploratory studyHai-Yang Yuan, Wen-Yue Liu, Gong Feng, et al.
Hepatology (Baltimore, Md.)|March 30, 2007
The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLDPaul Angulo, Jason M Hui, Giulio Marchesini, et al.
European Heart Journal|April 18, 2019
A randomized controlled trial of metformin on left ventricular hypertrophy in patients with coronary artery disease without diabetes: the MET-REMODEL trialMohapradeep Mohan, Shaween Al-Talabany, Angela McKinnie, et al.
Nature Genetics|September 15, 2009
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapyVijayaprakash Suppiah, Max Moldovan, Golo Ahlenstiel, et al.
Hepatology Communications|June 4, 2020
Impact of an Open Access Nationwide Treatment Model on Hepatitis C Virus Antiviral Drug ResistanceMark W Douglas, Enoch S E Tay, Dao Sen Wang, et al.
The Lancet. Gastroenterology & Hepatology|July 15, 2021
Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseasesMohammed Eslam, Aijaz Ahmed, Jean-Pierre Després, et al.
Journal of Hepatology|April 29, 2014
IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infectionMohammed Eslam, Reynold Leung, Manuel Romero-Gomez, et al.
The Lancet. Gastroenterology & Hepatology|September 7, 2024
Global prevalence and characteristics of infections and clinical outcomes in hospitalised patients with cirrhosis: a prospective cohort study for the CLEARED ConsortiumZhujun Cao, Florence Wong, Ashok K Choudhury, et al.
Pageof 85

Showing results (721-730 of 849) with videos related to

Sort By:
Pageof 85
Metabolism: Clinical and Experimental|April 18, 2016
Opposite associations between alanine aminotransferase and γ-glutamyl transferase levels and all-cause mortality in type 2 diabetes: Analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) studyKathryn H Williams, David R Sullivan, Geoffrey C Nicholson, et al.
Hepatology (Baltimore, Md.)|January 18, 2013
Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infectionJason Grebely, Jordan J Feld, Tanya Applegate, et al.
Diabetes, Obesity & Metabolism|September 17, 2024
Associations between cuprotosis-related genes and the spectrum of metabolic dysfunction-associated fatty liver disease: An exploratory studyHai-Yang Yuan, Wen-Yue Liu, Gong Feng, et al.
Hepatology (Baltimore, Md.)|March 30, 2007
The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLDPaul Angulo, Jason M Hui, Giulio Marchesini, et al.
European Heart Journal|April 18, 2019
A randomized controlled trial of metformin on left ventricular hypertrophy in patients with coronary artery disease without diabetes: the MET-REMODEL trialMohapradeep Mohan, Shaween Al-Talabany, Angela McKinnie, et al.
Nature Genetics|September 15, 2009
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapyVijayaprakash Suppiah, Max Moldovan, Golo Ahlenstiel, et al.
Hepatology Communications|June 4, 2020
Impact of an Open Access Nationwide Treatment Model on Hepatitis C Virus Antiviral Drug ResistanceMark W Douglas, Enoch S E Tay, Dao Sen Wang, et al.
The Lancet. Gastroenterology & Hepatology|July 15, 2021
Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseasesMohammed Eslam, Aijaz Ahmed, Jean-Pierre Després, et al.
Journal of Hepatology|April 29, 2014
IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infectionMohammed Eslam, Reynold Leung, Manuel Romero-Gomez, et al.
The Lancet. Gastroenterology & Hepatology|September 7, 2024
Global prevalence and characteristics of infections and clinical outcomes in hospitalised patients with cirrhosis: a prospective cohort study for the CLEARED ConsortiumZhujun Cao, Florence Wong, Ashok K Choudhury, et al.
Pageof 85